Tsai Alexander C, Weiser Sheri D, Petersen Maya L, Ragland Kathleen, Kushel Margot B, Bangsberg David R
Langley Porter Psychiatric Institute, University of California at San Francisco, USA.
Arch Gen Psychiatry. 2010 Dec;67(12):1282-90. doi: 10.1001/archgenpsychiatry.2010.160.
Depression strongly predicts nonadherence to human immunodeficiency virus (HIV) antiretroviral therapy, and adherence is essential to maintaining viral suppression. This suggests that pharmacologic treatment of depression may improve virologic outcomes. However, previous longitudinal observational analyses have inadequately adjusted for time-varying confounding by depression severity, which could yield biased estimates of treatment effect. Application of marginal structural modeling to longitudinal observation data can, under certain assumptions, approximate the findings of a randomized controlled trial.
To determine whether antidepressant medication treatment increases the probability of HIV viral suppression.
Community-based prospective cohort study with assessments conducted every 3 months.
Community-based research field site in San Francisco, California.
One hundred fifty-eight homeless and marginally housed persons with HIV who met baseline immunologic (CD4+ T-lymphocyte count, <350/μL) and psychiatric (Beck Depression Inventory II score, >13) inclusion criteria, observed from April 2002 through August 2007.
Probability of achieving viral suppression to less than 50 copies/mL. Secondary outcomes of interest were probability of being on an antiretroviral therapy regimen, 7-day self-reported percentage adherence to antiretroviral therapy, and probability of reporting complete (100%) adherence.
Marginal structural models estimated a 2.03 greater odds of achieving viral suppression (95% confidence interval [CI], 1.15-3.58; P = .02) resulting from antidepressant medication treatment. In addition, antidepressant medication use increased the probability of antiretroviral uptake (weighted odds ratio, 3.87; 95% CI, 1.98-7.58; P < .001). Self-reported adherence to antiretroviral therapy increased by 25 percentage points (95% CI, 14-36; P < .001), and the odds of reporting complete adherence nearly doubled (weighted odds ratio, 1.94; 95% CI, 1.20-3.13; P = .006).
Antidepressant medication treatment increases viral suppression among persons with HIV. This effect is likely attributable to improved adherence to a continuum of HIV care, including increased uptake and adherence to antiretroviral therapy.
抑郁症是预测人类免疫缺陷病毒(HIV)抗逆转录病毒治疗依从性差的重要因素,而维持病毒抑制必须保证治疗依从性。这表明对抑郁症进行药物治疗可能会改善病毒学治疗效果。然而,以往的纵向观察分析未能充分调整随时间变化的抑郁症严重程度混杂因素,这可能会导致治疗效果的估计出现偏差。在某些假设条件下,将边际结构模型应用于纵向观察数据,可以近似得出随机对照试验的结果。
确定抗抑郁药物治疗是否能提高HIV病毒抑制的概率。
以社区为基础的前瞻性队列研究,每3个月进行一次评估。
加利福尼亚州旧金山的社区研究现场。
158名符合基线免疫学(CD4 + T淋巴细胞计数,<350/μL)和精神病学(贝克抑郁量表II评分,>13)纳入标准的HIV感染者,这些人无家可归或居住条件差,研究时间为2002年4月至2007年8月。
实现病毒抑制至低于50拷贝/mL的概率。感兴趣的次要指标包括接受抗逆转录病毒治疗方案的概率、自我报告的7天抗逆转录病毒治疗依从率以及报告完全(100%)依从的概率。
边际结构模型估计,抗抑郁药物治疗使实现病毒抑制的几率提高了2.03倍(95%置信区间[CI],1.15 - 3.58;P = 0.02)。此外,使用抗抑郁药物增加了接受抗逆转录病毒治疗的概率(加权优势比,3.87;95%CI,1.98 - 7.58;P < 0.001)。自我报告的抗逆转录病毒治疗依从率提高了25个百分点(95%CI,14 - 36;P < 0.001),报告完全依从的几率几乎翻倍(加权优势比,1.94;95%CI,1.20 - 3.13;P = 0.006)。
抗抑郁药物治疗可提高HIV感染者的病毒抑制水平。这种效果可能归因于对HIV连续护理的依从性提高,包括增加抗逆转录病毒治疗的接受度和依从性。